ENT and Allergy Associates(R) adds Depth and Breadth of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ENT and Allergy Associates(R) adds Depth and Breadth of Expertise to its Team in Bridgewater, New Jersey

TARRYTOWN, N.Y., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Nothing is more important to a community than access to expert medical care as quickly and easily as possible.

ENT and Allergy Associates, LLP (ENTA) fully understands this priority. For this reason, ENTA provides its patients with the convenience of same day appointments, and now answers calls as early as 7:00AM in order to schedule these appointments.

And the nation's leading ear, nose, throat, allergy and audiology practice likewise continues to expand its roster of superior clinicians.

Today, ENTA proudly announced that Dr. Mena Abrahim will join its Bridgewater, New Jersey office, located at 245 US Highway 22, in the Fall of 2016. He will become the 175th board certified clinician in ENTA's network of 42 offices throughout New York and New Jersey.

Dr. Mena Abrahim, raised in New York City, graduated Cum Laude from CUNY Brooklyn in 2003 and went on to earn his Doctorate in Osteopathic Medicine from New York College of Osteopathic Medicine (NYCOM) in Long Island, New York. He then completed a general surgery internship and an Otolaryngology-Head and Neck Surgery/Facial Plastics residency at Philadelphia College of Osteopathic Medicine (PCOM) where he served as Co-Chief Resident of the program. Dr. Abrahim is a member of the American Osteopathic Association, the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and the American Osteopathic Colleges of Ophthalmology and Otolaryngology.

In Bridgewater, Dr. Abrahim will serve both adult and pediatric patients for their general ENT needs. He will join esteemed colleagues including otolaryngologists Dr. Amy Lazar, Dr. Adrianna Hekiert, Dr. Dennis Burachinsky (specializing in facial plastics) and Dr. Marie Camacho-Halili (Allergist/Immunologist).

"We have long served the needs of those in Bridgewater and surrounding communities by ensuring they receive the best medical treatment possible," commented Dr. Amy Lazar, ENT otolaryngologist in ENTA's Bridgewater office. "I am confident Dr. Abrahim will deliver that same level of superb care when he joins us."

Fellow Bridgewater otolaryngologist Dr. Adrianna Hekiert added, "We proudly define ourselves as a medical practice focused on delivering leading edge patient healthcare solutions. We welcome Dr. Abrahim and his talents, training, and dedication, which will most certainly allow us to help even more patients in our surrounding neighborhoods."

Robert Glazer, CEO of ENTA, noted "Increasing patient access to our services is a top priority of our Practice.  That's why we ensure that patients who call our offices are offered same day appointments to the extent possible. And that's why we are so delighted to be able to add a physician of Dr. Abrahim's skills and pedigree."

To learn more about the benefits of ENT and Allergy Associates, find the office near you or schedule an appointment, please visit www.entandallergy.com or call 1-855-ENTA-DOC as early as 7:00am.

About ENT and Allergy Associates, LLP:

ENT and Allergy has over 170 physicians practicing in 40+ office locations in Westchester, Putnam, Orange, Dutchess, Rockland, Nassau and Suffolk counties, New York City and northern/central New Jersey. The practice sees over 70,000 patients per month. Each ENT and Allergy Associates clinical location provides access to a full complement of services, including General Adult and Pediatric ENT, Voice and Swallowing, Facial Plastics and Reconstructive Surgery, Disorders of the Inner Ear and Dizziness, Asthma, Clinical Immunology, Diagnostic Audiology, Hearing Aid dispensing, Sleep and CT Services. ENTA has a clinical alliance with The Mount Sinai Hospital for the treatment of diseases of the head and neck and esophageal cancer, a clinical alliance with the Montefiore Medical Center for the tertiary treatment of pediatric patients in New York City and the Hudson Valley, a clinical alliance with the North Shore-Long Island Jewish Health System for the tertiary treatment of pediatric patients in Nassau and Suffolk Counties and a partnership with the American Cancer Society to educate and treat patients with smoking disorders and cancer. The Practice has also expanded its clinical capabilities to include advanced Immunodeficiency trials. ENT and Allergy Associates Management and Marketing teams have been recognized numerous times with awards and accolades including Health Leaders Media 2011 Top Leadership Team in Healthcare, Top Doctor awards, ACS recognition award, AHAA Audiologist awards, The Westchester County Association Big W Awards and the Healthcare Marketing Report Healthcare Advertising Awards. Visit www.entandallergy.com for more information.

A photo accompanying this release is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=38425

Keith Arluna 560 White Plains Rd, Suite 615 Tarrytown, NY 10591 Office: 914-298-5061 Cell: 914-575-1934

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 204

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 127

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 170

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 197

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 150

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 303

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 309

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 148

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 108

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 268

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading

Top 5 Most Recently Viewed Articles

Healthcare Realty Trust's Q4 Highlights and Dividend Update

Updated Category News Views 112

Healthcare Realty Trust Quarterly Results Overview Healthcare Realty Trust Incorporated (NYSE: HR) has reported its fourth quarter results for the year 2024, highlighting significant developments in its operations and financial performance. The company recorded a net (loss) income attributable to common stockholders of $(106.8) million, or $(0.31) per diluted share,...

Continue Reading
BGL's Strategic Move: Selling Western Botanicals to Riverside

Updated Category News Views 322

Brown Gibbons Lang & Company (BGL) has just sealed the deal on a significant sale—Western Botanicals, a prominent player in the Vitamins, Minerals, and Supplements (VMS) contract development and manufacturing space, is headed to The Riverside Company. Now this isn’t just another corporate shuffle; it's BGL’s third foray into the CDMO subsector and marks their fourth...

Continue Reading
High Arctic Energy Services Reports Second Quarter 2025 Success

Updated Category News Views 225

High Arctic Energy Services Reports Strong Second Quarter Results High Arctic Energy Services Inc. (TSX: HWO), a noted energy services provider, has recently shared its financial results for the second quarter of 2025, highlighting a continued commitment to operational excellence amid challenging market conditions. 2025 Second Quarter Performance Overview The company...

Continue Reading
DXC Technology Investors Notified of Securities Class Action

Updated Category News Views 45

DXC Technology Class Action Notice for Shareholders The Gross Law Firm has released an important notice for shareholders of DXC Technology Company (NYSE: DXC). This notice is aimed at individuals who acquired shares during the specified class period. Shareholders are encouraged to reach out to the firm if they are interested in being considered for the role of lead...

Continue Reading
Manulife's $750M US Offering: Risky or Strategic?

Updated Category News Views 50

Manulife: Debuting $750M in Subordinated Notes When it comes to Manulife's latest move, it's all about the numbers. They've priced a U.S. public offering of a meaty $750 million in subordinated notes at an enticing 6.146% interest rate. That's no pocket change, folks, and it highlights a strategy or a gamble, depending on your view. But here's the kicker: these notes may...

Continue Reading